Detalhe da pesquisa
1.
Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN.
Br J Cancer
; 130(1): 73-81, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37951974
2.
Prostate-specific antigen (PSA) decline with apalutamide therapy is associated with longer survival and improved outcomes in individuals with metastatic prostate cancer: a plain language summary of the TITAN study.
Future Oncol
; 20(10): 563-578, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38126311
3.
Efficacy and Safety of Ranibizumab 0.5 mg for the Treatment of Macular Edema Resulting from Uncommon Causes: Twelve-Month Findings from PROMETHEUS.
Ophthalmology
; 125(6): 850-862, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29371007
6.
Coadministration of Apalutamide and Relugolix in Patients with Localized Prostate Cancer at High Risk for Metastases.
Target Oncol
; 18(1): 95-103, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36472728
7.
Post Hoc Analysis of Rapid and Deep Prostate-specific Antigen Decline and Patient-reported Health-related Quality of Life in SPARTAN and TITAN Patients with Advanced Prostate Cancer.
Eur Urol Oncol
; 2023 Dec 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38072759
8.
Apalutamide for metastatic castration-sensitive prostate cancer: final analysis of the Asian subpopulation in the TITAN trial.
Asian J Androl
; 25(6): 653-661, 2023 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37322621
9.
Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer: A subgroup analysis of the randomised clinical TITAN study.
Eur J Cancer
; 193: 113290, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37708629
10.
Clinical characteristics associated with falls in patients with non-metastatic castration-resistant prostate cancer treated with apalutamide.
Prostate Cancer Prostatic Dis
; 26(1): 156-161, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36209239
11.
Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTAN.
Eur Urol
; 81(2): 184-192, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-34916086
12.
Concomitant use of oral anticoagulants in patients with advanced prostate cancer receiving apalutamide: A post-hoc analysis of TITAN and SPARTAN studies.
Am J Cancer Res
; 12(1): 445-450, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35141028
13.
Safety and tolerability of fixed-dose irbesartan/hydrochlorothiazide for rapid control of severe hypertension.
Clin Exp Hypertens
; 31(7): 572-84, 2009 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-19886855
14.
Correction to: Clinical characteristics associated with falls in patients with non-metastatic castration-resistant prostate cancer treated with apalutamide.
Prostate Cancer Prostatic Dis
; 26(4): 813, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37620428
15.
The efficacy and safety of initial use of irbesartan/hydrochlorothiazide fixed-dose combination in hypertensive patients with and without high cardiovascular risk.
J Clin Hypertens (Greenwich)
; 9(12 Suppl 5): 23-30, 2007 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-18046109
16.
Efficacy and safety of irbesartan/HCTZ combination therapy as initial treatment for rapid control of severe hypertension.
J Clin Hypertens (Greenwich)
; 8(12): 850-7; quiz 858-9, 2006 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-17170610
17.
Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: a case for albuminuria.
Kidney Int Suppl
; (92): S50-5, 2004 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-15485418
18.
Safety and immunogenicity of an inactivated quadrivalent influenza vaccine in children 6 months through 8 years of age.
Pediatr Infect Dis J
; 33(6): 630-6, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24445833